Evoke Pharma INC 10-K annual reports

Evoke Pharma's 10-K filing highlights a significant increase in Gimoti sales, but also acknowledges substantial doubt about the company's ability to continue as a going concern due to recurring losses.

Evoke Pharma has amended its annual report to restate financial statements due to a classification error related to a note payable, also identifying a material weakness in internal controls.

Evoke Pharma's 2023 annual report highlights increased Gimoti sales and ongoing efforts to manage costs and secure future funding.